SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point-of-care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer in augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making.
SciBase’s products include Nevisense and Nevisense Go and to date, the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection, and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase’s technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden.